In both combined groups, 2 patients acquired bleeding at two sites. Main or relevant bleeding occurred in 80 patients in the dabigatran group and 145 patients in the warfarin group . The risk of any bleeding can be shown in Figure 2AFigure 2Cumulative Threat of Any Bleeding. There were no significant variations in the risk of bleeding regarding to study treatment in predefined subgroups. We observed a higher incidence of acute coronary events in the dabigatran group than in the warfarin group . All these occasions had been adjudicated as definite aside from myocardial infarction in 1 patient in the dabigatran group and unstable angina in 1 individual in the warfarin group. In each group, 1 patient had an event within 3 times after stopping the scholarly research treatment.Dr. Nagle concludes, Kheterpal and co-workers ought to be congratulated for cautiously using their institution’s huge databases and reporting potential risk elements that will hopefully result in further investigations and, in the future someday, improvements that may lower this main perioperative complication. .
AMGA reviews success in first two regional meetings about ACOs The American Medical Group Association announced that the first two meetings in a series of regional meetings centered on accountable care organizations were unqualified successes, drawing healthcare leaders together to network within an intimate setting and to study from leading medical groups and organized systems of care that are exemplars of the ACO model.